Literature DB >> 17339584

Temporal relationship between cigarette smoking and risk of Parkinson disease.

E L Thacker1, E J O'Reilly, M G Weisskopf, H Chen, M A Schwarzschild, M L McCullough, E E Calle, M J Thun, A Ascherio.   

Abstract

OBJECTIVE: To characterize further the relationship between smoking history and Parkinson disease (PD) risk by considering temporal and qualitative features of smoking exposure, including duration, average intensity, and recentness, as well as the relative importance of smoking during different periods of life.
METHODS: We prospectively assessed incident PD from 1992 to 2001 among 79,977 women and 63,348 men participating in the Cancer Prevention Study II Nutrition Cohort, according to their cigarette smoking status and lifetime smoking histories.
RESULTS: During follow-up, 413 participants had definite or probable PD confirmed by their treating neurologists or medical record review. Compared with never smokers, former smokers had a relative risk (RR) of 0.78 (95% CI 0.64 to 0.95) and current smokers had an RR of 0.27 (95% CI 0.13 to 0.56). On average, participants with more years smoked, more cigarettes per day, older age at quitting smoking, and fewer years since quitting smoking had lower PD risk. The relative risks and trends did not vary significantly by sex. The cumulative incidence of PD was lowest among participants who quit smoking at later ages. A 30% to 60% decreased risk of PD was apparent for smoking as early as 15 to 24 years before symptom onset, but not for smoking 25 or more years before onset.
CONCLUSIONS: The lower risk of Parkinson disease among current and former smokers varied with smoking duration, intensity, and recentness. The dependence of this association on the timing of smoking during life is consistent with a biologic effect.

Entities:  

Mesh:

Year:  2007        PMID: 17339584      PMCID: PMC2225169          DOI: 10.1212/01.wnl.0000256374.50227.4b

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  20 in total

1.  Risk factors for parkinson's disease: the leisure world cohort study.

Authors:  A Paganini-Hill
Journal:  Neuroepidemiology       Date:  2001-05       Impact factor: 3.282

2.  The ever-stimulating association of smoking and coffee and Parkinson's disease.

Authors:  Karen Marder; Giancarlo Logroscino
Journal:  Ann Neurol       Date:  2002-09       Impact factor: 10.422

3.  The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service.

Authors:  Andrew J Hughes; Susan E Daniel; Yoav Ben-Shlomo; Andrew J Lees
Journal:  Brain       Date:  2002-04       Impact factor: 13.501

4.  Selection, follow-up, and analysis in the American Cancer Society prospective studies.

Authors:  L Garfinkel
Journal:  Natl Cancer Inst Monogr       Date:  1985-05

5.  The American Cancer Society Cancer Prevention Study II Nutrition Cohort: rationale, study design, and baseline characteristics.

Authors:  Eugenia E Calle; Carmen Rodriguez; Eric J Jacobs; M Lyn Almon; Ann Chao; Marjorie L McCullough; Heather S Feigelson; Michael J Thun
Journal:  Cancer       Date:  2002-05-01       Impact factor: 6.860

6.  Improved accuracy of clinical diagnosis of Lewy body Parkinson's disease.

Authors:  A J Hughes; S E Daniel; A J Lees
Journal:  Neurology       Date:  2001-10-23       Impact factor: 9.910

7.  Smoking, alcohol, and coffee consumption preceding Parkinson's disease: a case-control study.

Authors:  M D Benedetti; J H Bower; D M Maraganore; S K McDonnell; B J Peterson; J E Ahlskog; D J Schaid; W A Rocca
Journal:  Neurology       Date:  2000-11-14       Impact factor: 9.910

Review 8.  Current evidence for neuroprotective effects of nicotine and caffeine against Parkinson's disease.

Authors:  G W Ross; H Petrovitch
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

9.  Cigarette smoking and the incidence of Parkinson's disease in two prospective studies.

Authors:  M A Hernán; S M Zhang; A M Rueda-deCastro; G A Colditz; F E Speizer; A Ascherio
Journal:  Ann Neurol       Date:  2001-12       Impact factor: 10.422

Review 10.  Smoking, nicotine and Parkinson's disease.

Authors:  Maryka Quik
Journal:  Trends Neurosci       Date:  2004-09       Impact factor: 13.837

View more
  70 in total

1.  Premotor Parkinson's disease: concepts and definitions.

Authors:  Andrew Siderowf; Anthony E Lang
Journal:  Mov Disord       Date:  2012-04-15       Impact factor: 10.338

Review 2.  α6β2* and α4β2* nicotinic acetylcholine receptors as drug targets for Parkinson's disease.

Authors:  Maryka Quik; Susan Wonnacott
Journal:  Pharmacol Rev       Date:  2011-12       Impact factor: 25.468

Review 3.  Targeting nicotinic receptors for Parkinson's disease therapy.

Authors:  Maryka Quik; Tanuja Bordia; Luping Huang; Xiomara Perez
Journal:  CNS Neurol Disord Drug Targets       Date:  2011-09-01       Impact factor: 4.388

4.  Risk for Parkinson's disease among patients with osteoarthritis: a Danish cohort study.

Authors:  Kathrine Rugbjerg; Søren Friis; Thomas L Jørgensen; Beate Ritz; Lise Korbo; Jørgen H Olsen
Journal:  Mov Disord       Date:  2010-10-30       Impact factor: 10.338

5.  Focus on α4β2* and α6β2* nAChRs for Parkinson's Disease Therapeutics.

Authors:  Xiomara A Pérez; Maryka Quik
Journal:  Mol Cell Pharmacol       Date:  2011

Review 6.  Mysterious alpha6-containing nAChRs: function, pharmacology, and pathophysiology.

Authors:  Ke-chun Yang; Guo-zhang Jin; Jie Wu
Journal:  Acta Pharmacol Sin       Date:  2009-06       Impact factor: 6.150

7.  Non-genetic factors associated with the risk of Parkinson's disease in Iranian patients.

Authors:  N Hosseini Tabatabaei; B Babakhani; A Hosseini Tabatabaei; Z Vahabi; A Soltanzadeh
Journal:  Funct Neurol       Date:  2013 Apr-May

8.  Inflammation and oxidative stress induced by cigarette smoke in Lewis rat brains.

Authors:  A Khanna; M Guo; M Mehra; W Royal
Journal:  J Neuroimmunol       Date:  2012-09-30       Impact factor: 3.478

Review 9.  Olfactory Dysfunction in Neurodegenerative Diseases.

Authors:  Concepció Marin; Dolores Vilas; Cristóbal Langdon; Isam Alobid; Mauricio López-Chacón; Antje Haehner; Thomas Hummel; Joaquim Mullol
Journal:  Curr Allergy Asthma Rep       Date:  2018-06-15       Impact factor: 4.806

Review 10.  Duality of Antidepressants and Neuroprotectants.

Authors:  Yousef Tizabi
Journal:  Neurotox Res       Date:  2015-11-27       Impact factor: 3.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.